Cargando…
A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy
The indication for neoadjuvant chemotherapy (NAC) has recently broadened to include its use in the treatment of initial stage breast cancer. Axillary lymph node metastasis after NAC in breast cancer is a poor prognostic factor. Thus, the prediction of lymph node metastasis is important to estimate t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811402/ https://www.ncbi.nlm.nih.gov/pubmed/26935647 http://dx.doi.org/10.3892/or.2016.4635 |
_version_ | 1782423947464146944 |
---|---|
author | MOROHASHI, SATOKO YOSHIZAWA, TADASHI SEINO, HIROKO HIRAI, HIDEAKI HAGA, TOSHIHIRO OTA, RIE WU, YUNYAN YOSHIDA, ERI HAKAMADA, KENICHI KIJIMA, HIROSHI |
author_facet | MOROHASHI, SATOKO YOSHIZAWA, TADASHI SEINO, HIROKO HIRAI, HIDEAKI HAGA, TOSHIHIRO OTA, RIE WU, YUNYAN YOSHIDA, ERI HAKAMADA, KENICHI KIJIMA, HIROSHI |
author_sort | MOROHASHI, SATOKO |
collection | PubMed |
description | The indication for neoadjuvant chemotherapy (NAC) has recently broadened to include its use in the treatment of initial stage breast cancer. Axillary lymph node metastasis after NAC in breast cancer is a poor prognostic factor. Thus, the prediction of lymph node metastasis is important to estimate the prognosis of breast cancer patients after NAC. Therefore, we focused on residual carcinoma patterns of primary breast tumors after NAC and examined the correlation between the patterns and lymph node metastasis. In this study, we examined 50 breast cancer specimens and associated dissected lymph nodes after NAC. We divided 40 cases into an eradicated lymph node group and a residual lymph node group to analyze residual carcinoma patterns of primary breast tumors. Residual carcinoma patterns were classified according to the cell density of carcinoma cells: dense, focal/nested and sporadic/in-situ. There were significant differences in residual carcinoma patterns (P<0.01) among the three pattern groups. There was a high incidence of dense patterns in the residual lymph node group and a high incidence of sporadic/in-situ patterns in the eradicated lymph node group. Analysis of residual carcinoma patterns of primary breast tumors and clinicopathological factors demonstrated that there were significant differences in tumor reduced ratio on CT (P<0.001), primary tumor area before NAC (P<0.01), primary tumor area after NAC (P<0.00001), intrinsic subtype (P<0.01), Ki-67 labeling index (P<0.01), histological grade (P<0.05) and mitotic count (P<0.01) between the dense and non-dense groups. Therefore, our results suggest that the residual carcinoma pattern is useful for predicting eradicated or residual lymph nodes and the malignant potential in breast cancer after NAC. |
format | Online Article Text |
id | pubmed-4811402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-48114022016-04-06 A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy MOROHASHI, SATOKO YOSHIZAWA, TADASHI SEINO, HIROKO HIRAI, HIDEAKI HAGA, TOSHIHIRO OTA, RIE WU, YUNYAN YOSHIDA, ERI HAKAMADA, KENICHI KIJIMA, HIROSHI Oncol Rep Articles The indication for neoadjuvant chemotherapy (NAC) has recently broadened to include its use in the treatment of initial stage breast cancer. Axillary lymph node metastasis after NAC in breast cancer is a poor prognostic factor. Thus, the prediction of lymph node metastasis is important to estimate the prognosis of breast cancer patients after NAC. Therefore, we focused on residual carcinoma patterns of primary breast tumors after NAC and examined the correlation between the patterns and lymph node metastasis. In this study, we examined 50 breast cancer specimens and associated dissected lymph nodes after NAC. We divided 40 cases into an eradicated lymph node group and a residual lymph node group to analyze residual carcinoma patterns of primary breast tumors. Residual carcinoma patterns were classified according to the cell density of carcinoma cells: dense, focal/nested and sporadic/in-situ. There were significant differences in residual carcinoma patterns (P<0.01) among the three pattern groups. There was a high incidence of dense patterns in the residual lymph node group and a high incidence of sporadic/in-situ patterns in the eradicated lymph node group. Analysis of residual carcinoma patterns of primary breast tumors and clinicopathological factors demonstrated that there were significant differences in tumor reduced ratio on CT (P<0.001), primary tumor area before NAC (P<0.01), primary tumor area after NAC (P<0.00001), intrinsic subtype (P<0.01), Ki-67 labeling index (P<0.01), histological grade (P<0.05) and mitotic count (P<0.01) between the dense and non-dense groups. Therefore, our results suggest that the residual carcinoma pattern is useful for predicting eradicated or residual lymph nodes and the malignant potential in breast cancer after NAC. D.A. Spandidos 2016-05 2016-02-25 /pmc/articles/PMC4811402/ /pubmed/26935647 http://dx.doi.org/10.3892/or.2016.4635 Text en Copyright: © Morohashi et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles MOROHASHI, SATOKO YOSHIZAWA, TADASHI SEINO, HIROKO HIRAI, HIDEAKI HAGA, TOSHIHIRO OTA, RIE WU, YUNYAN YOSHIDA, ERI HAKAMADA, KENICHI KIJIMA, HIROSHI A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy |
title | A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy |
title_full | A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy |
title_fullStr | A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy |
title_full_unstemmed | A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy |
title_short | A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy |
title_sort | new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811402/ https://www.ncbi.nlm.nih.gov/pubmed/26935647 http://dx.doi.org/10.3892/or.2016.4635 |
work_keys_str_mv | AT morohashisatoko anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT yoshizawatadashi anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT seinohiroko anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT hiraihideaki anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT hagatoshihiro anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT otarie anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT wuyunyan anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT yoshidaeri anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT hakamadakenichi anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT kijimahiroshi anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT morohashisatoko newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT yoshizawatadashi newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT seinohiroko newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT hiraihideaki newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT hagatoshihiro newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT otarie newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT wuyunyan newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT yoshidaeri newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT hakamadakenichi newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy AT kijimahiroshi newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy |